JP2004507444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004507444A5 JP2004507444A5 JP2001554669A JP2001554669A JP2004507444A5 JP 2004507444 A5 JP2004507444 A5 JP 2004507444A5 JP 2001554669 A JP2001554669 A JP 2001554669A JP 2001554669 A JP2001554669 A JP 2001554669A JP 2004507444 A5 JP2004507444 A5 JP 2004507444A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- administered
- group
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 57
- 108010062745 Chloride Channels Proteins 0.000 description 6
- 102000011045 Chloride Channels Human genes 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 201000003883 Cystic fibrosis Diseases 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical group COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010025476 Malabsorption Diseases 0.000 description 2
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 229960002146 guaifenesin Drugs 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960005262 talniflumate Drugs 0.000 description 2
- -1 flavorings Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003227 purinergic agonist Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17912700P | 2000-01-31 | 2000-01-31 | |
| US19311100P | 2000-03-30 | 2000-03-30 | |
| US23078300P | 2000-09-07 | 2000-09-07 | |
| US24213400P | 2000-10-23 | 2000-10-23 | |
| US25205200P | 2000-11-20 | 2000-11-20 | |
| PCT/US2001/003078 WO2001054685A1 (en) | 2000-01-31 | 2001-01-31 | Mucin synthesis inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507444A JP2004507444A (ja) | 2004-03-11 |
| JP2004507444A5 true JP2004507444A5 (https=) | 2008-02-28 |
Family
ID=27539006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001554669A Pending JP2004507444A (ja) | 2000-01-31 | 2001-01-31 | ムチン合成インヒビター |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6737427B2 (https=) |
| EP (1) | EP1255544B1 (https=) |
| JP (1) | JP2004507444A (https=) |
| AR (1) | AR042578A1 (https=) |
| AT (1) | ATE355836T1 (https=) |
| AU (2) | AU2001234671B2 (https=) |
| CA (1) | CA2398642A1 (https=) |
| CY (1) | CY1106643T1 (https=) |
| DE (1) | DE60127098T2 (https=) |
| DK (1) | DK1255544T3 (https=) |
| ES (1) | ES2282235T3 (https=) |
| PT (1) | PT1255544E (https=) |
| WO (1) | WO2001054685A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE355836T1 (de) * | 2000-01-31 | 2007-03-15 | Genaera Corp | Inhibitoren der mucin-synthese |
| US20020147216A1 (en) * | 2000-01-31 | 2002-10-10 | Yuhong Zhou | Mucin synthesis inhibitors |
| US7345051B2 (en) * | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| US8474460B2 (en) | 2000-03-04 | 2013-07-02 | Pulmonx Corporation | Implanted bronchial isolation devices and methods |
| US6679264B1 (en) | 2000-03-04 | 2004-01-20 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
| US6904909B2 (en) | 2000-03-04 | 2005-06-14 | Emphasys Medical, Inc. | Methods and devices for use in performing pulmonary procedures |
| US20030059434A1 (en) * | 2000-08-09 | 2003-03-27 | Andrew Grupe | Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions |
| US7011094B2 (en) | 2001-03-02 | 2006-03-14 | Emphasys Medical, Inc. | Bronchial flow control devices and methods of use |
| US20030050648A1 (en) | 2001-09-11 | 2003-03-13 | Spiration, Inc. | Removable lung reduction devices, systems, and methods |
| CA2458595C (en) | 2001-10-11 | 2007-12-04 | Peter M. Wilson | Bronchial flow control devices and methods of use |
| US6592594B2 (en) | 2001-10-25 | 2003-07-15 | Spiration, Inc. | Bronchial obstruction device deployment system and method |
| US6818446B2 (en) | 2001-11-21 | 2004-11-16 | The Regents Of The University Of California | Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression |
| US6929637B2 (en) | 2002-02-21 | 2005-08-16 | Spiration, Inc. | Device and method for intra-bronchial provision of a therapeutic agent |
| US7412977B2 (en) | 2002-03-08 | 2008-08-19 | Emphasys Medical, Inc. | Methods and devices for inducing collapse in lung regions fed by collateral pathways |
| US20030216769A1 (en) | 2002-05-17 | 2003-11-20 | Dillard David H. | Removable anchored lung volume reduction devices and methods |
| US20030181922A1 (en) | 2002-03-20 | 2003-09-25 | Spiration, Inc. | Removable anchored lung volume reduction devices and methods |
| US20040059263A1 (en) | 2002-09-24 | 2004-03-25 | Spiration, Inc. | Device and method for measuring the diameter of an air passageway |
| CA2487405A1 (en) | 2002-07-26 | 2004-02-05 | Emphasys Medical, Inc. | Bronchial flow control devices with membrane seal |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US7100616B2 (en) | 2003-04-08 | 2006-09-05 | Spiration, Inc. | Bronchoscopic lung volume reduction method |
| MXPA05012728A (es) | 2003-05-28 | 2006-02-13 | Wyeth Corp | Clca-1 soluble y antagonistas para el clca-1. |
| AU2004249775A1 (en) * | 2003-06-19 | 2004-12-29 | Genaera Corporation | Mucin synthesis inhibitors |
| US7533671B2 (en) | 2003-08-08 | 2009-05-19 | Spiration, Inc. | Bronchoscopic repair of air leaks in a lung |
| JP2008507368A (ja) * | 2004-07-22 | 2008-03-13 | デュスカ サイエンティフィック カンパニー | 肺疾患を診断、モニタリングおよび治療するための方法 |
| US9211181B2 (en) | 2004-11-19 | 2015-12-15 | Pulmonx Corporation | Implant loading device and system |
| US7771472B2 (en) | 2004-11-19 | 2010-08-10 | Pulmonx Corporation | Bronchial flow control devices and methods of use |
| EP1827479A1 (en) * | 2004-12-09 | 2007-09-05 | Ingenium Pharmaceuticals AG | Methods and agents useful in treating conditions characterized by mucus hyperproduction/ hypersecretion |
| WO2006075172A2 (en) * | 2005-01-13 | 2006-07-20 | University Of Dundee | Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2 |
| US8876791B2 (en) | 2005-02-25 | 2014-11-04 | Pulmonx Corporation | Collateral pathway treatment using agent entrained by aspiration flow current |
| US7691151B2 (en) | 2006-03-31 | 2010-04-06 | Spiration, Inc. | Articulable Anchor |
| EP2043603A4 (en) | 2006-07-11 | 2010-10-27 | Arubor Corp | PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS |
| HUE048024T2 (hu) | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
| US8093246B2 (en) * | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
| US20100166726A1 (en) * | 2007-03-07 | 2010-07-01 | Northeastern University | Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation |
| JP5570993B2 (ja) | 2007-10-12 | 2014-08-13 | スピレーション インコーポレイテッド | 弁装填具の方法、システム、および装置 |
| GB0905954D0 (en) * | 2009-04-06 | 2009-05-20 | E Therapeutics Plc | Treatment of exacerbations of asthma |
| US9782454B2 (en) * | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| WO2012134965A1 (en) * | 2011-03-25 | 2012-10-04 | The Trustees Of Columbia University In The City Of New York | Chloride channel and chloride transporter modulators for therapy in smooth muscle diseases |
| WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
| WO2015182565A1 (ja) * | 2014-05-27 | 2015-12-03 | リンク・ジェノミクス株式会社 | 肺疾患治療剤 |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4168313A (en) | 1978-02-21 | 1979-09-18 | Sebastian Bago | Phthalidyl 2-(3'-trifluoromethyl-anilino)-pyridine-3-carboxylate and its salts |
| US4515980A (en) * | 1983-07-11 | 1985-05-07 | Sterling Drug Inc. | Substituted aminobenzoates, their preparation and use |
| US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| US4666716A (en) * | 1984-09-04 | 1987-05-19 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
| DE3682136D1 (de) * | 1985-07-31 | 1991-11-28 | Hoechst Ag | N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen. |
| DE3608726A1 (de) * | 1986-03-15 | 1987-09-17 | Hoechst Ag | Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen |
| GB9200114D0 (en) | 1992-01-04 | 1992-02-26 | Scras | Dual inhibitors of no synthase and cyclooxygenase |
| WO1996039419A1 (en) | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | Colon specific genes and proteins |
| EP0839031A1 (de) * | 1995-07-20 | 1998-05-06 | JUERGENS, Uwe R. | Verwendung eines nicht-steroidalen antiphlogistikums zur topischen und systemischen behandlung der akuten und chronischen polypoiden rhinosinusitis |
| US5875776A (en) * | 1996-04-09 | 1999-03-02 | Vivorx Pharmaceuticals, Inc. | Dry powder inhaler |
| SI0964865T1 (en) * | 1997-01-08 | 2003-08-31 | Pharmacia & Upjohn Company | Pharmaceutically active tricyclic amines |
| AU5610398A (en) * | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| BR9810385A (pt) * | 1997-07-01 | 2000-09-05 | Warner Lambert Co | Derivados de ácido benzóico 2-(4-bromo ou 4-iodo fenilamino) e sua utilização como inibidores de mek |
| US6136539A (en) * | 1998-02-11 | 2000-10-24 | The Regents Of The University Of California | Compositions and methods for the inhibition of MUC-5 mucin gene expression |
| US6576434B1 (en) | 1998-03-03 | 2003-06-10 | Genaera Corporation | Methods for identification of agents which modulate chloride channel activity |
| EP1140062B1 (en) * | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Treatment of asthma with mek inhibitors |
| DE69926914T2 (de) * | 1999-01-13 | 2006-06-29 | Warner-Lambert Co. Llc | 1-heterozyklus-substituierte diarylaminen |
| CA2349832A1 (en) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| US6245320B1 (en) * | 1999-09-01 | 2001-06-12 | University Of Maryland | Inhibition of mucin release from airway goblet cells by polycationic peptides |
| AU7965000A (en) * | 1999-09-27 | 2001-04-30 | Jun-Suk Oh | Use of analgesics as digestive and medicines for expectorating and transdermal therapeutic system using the same |
| ATE355836T1 (de) | 2000-01-31 | 2007-03-15 | Genaera Corp | Inhibitoren der mucin-synthese |
| GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
-
2001
- 2001-01-31 AT AT01906804T patent/ATE355836T1/de not_active IP Right Cessation
- 2001-01-31 DE DE60127098T patent/DE60127098T2/de not_active Expired - Fee Related
- 2001-01-31 CA CA002398642A patent/CA2398642A1/en not_active Abandoned
- 2001-01-31 AU AU2001234671A patent/AU2001234671B2/en not_active Ceased
- 2001-01-31 JP JP2001554669A patent/JP2004507444A/ja active Pending
- 2001-01-31 PT PT01906804T patent/PT1255544E/pt unknown
- 2001-01-31 AU AU3467101A patent/AU3467101A/xx active Pending
- 2001-01-31 US US09/774,243 patent/US6737427B2/en not_active Expired - Fee Related
- 2001-01-31 EP EP01906804A patent/EP1255544B1/en not_active Expired - Lifetime
- 2001-01-31 DK DK01906804T patent/DK1255544T3/da active
- 2001-01-31 ES ES01906804T patent/ES2282235T3/es not_active Expired - Lifetime
- 2001-01-31 WO PCT/US2001/003078 patent/WO2001054685A1/en not_active Ceased
- 2001-01-31 AR ARP010100437A patent/AR042578A1/es not_active Application Discontinuation
-
2004
- 2004-05-05 US US10/838,338 patent/US7504409B2/en not_active Expired - Fee Related
-
2007
- 2007-06-05 CY CY20071100747T patent/CY1106643T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004507444A5 (https=) | ||
| Wise | Changing smoking patterns and mortality from chronic obstructive pulmonary disease | |
| AU738298B2 (en) | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions | |
| Panitch | Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction | |
| JP2010503731A5 (https=) | ||
| US20050043321A1 (en) | Method for treating atopic disorders | |
| NO20061254L (no) | Farmasoytiske blandinger | |
| JP2005531584A5 (https=) | ||
| CA2733294A1 (en) | Pharmaceutical combination of a tiotropium salt and ciclesonide | |
| RU2003131178A (ru) | Агонисты никотиновых рецепторов для лечения воспалительных заболеваний | |
| Buhl et al. | Current and future pharmacologic therapy of exacerbations in chronic obstructive pulmonary disease and asthma | |
| Rubin | The pharmacologic approach to airway clearance: mucoactive agents | |
| WO2001032163A1 (en) | NEW COMBINATION COMPRISING A BETA 2 (β)2 ADRENO RECEPTOR AGONIST AND A LENKOTRIENE RECEPTOR ANTAGONIST | |
| JP2025510096A5 (https=) | ||
| US6100244A (en) | Method for treating respiratory distress by sublingual administration of DNA | |
| JP2023521634A5 (https=) | ||
| CA2323213C (en) | Treatment of respiratory disease and otitis media | |
| Rubin et al. | Mucoactive agents: old and new | |
| EP2114407B1 (en) | Use of sodium blockers for an early therapy of obstructive lung diseases | |
| JP2002338494A5 (https=) | ||
| Martinón-Torres | Current treatment for acute viral bronchiolitis in infants | |
| Lei et al. | Effect of Daiqin phlegm-expelling pill on development of inflammation in rats with chronic obstructive pulmonary disease induced by lipopolysaccharide and smoke. | |
| Varon et al. | Managing acute severe asthma: what therapies to try, and when; how to quickly assess and reduce airway obstruction | |
| RU2008102656A (ru) | Введение в дыхательные пути активированного белка с при воспалительных состояниях, поражающих дыхательные пути | |
| Shah | Treatment of Asthma and COPD |